NovalGen presents data at American Society of Clinical Oncology for novel ROR1xCD3 bispecific antibody for non-Hodgkin lymphoma
20 May 2021
London, United Kingdom, May 20, 2021 – NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, announced the company will give a poster presentation at the American Society of Clinical Oncology (“ASCO”) Annual meeting 2021, taking place June 4-8, 2021.
NovalGen has developed an ROR1xCD3 bispecific antibody T cell engager, NVG-111, that is currently entering Phase 1/2 development for patients with non-Hodgkin lymphoma; initially focused on Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL), but with the potential to target >20 different hard-to-treat solid and liquid cancers. NVG-111 is a first in class bispecific antibody T cell engager targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). ROR1 is a tumor-associated antigen that is overexpressed in a broad range of cancers, but has negligible expression in healthy adult tissues, making it an ideal candidate for novel, targeted cancer therapies.
“These data presented in our poster at ASCO show preclinical data supporting our Phase 1/2 first in human study for NVG-111,” said Professor Amit Nathwani, CEO of NovalGen. “The data demonstrates NVG-111 eliciting potent killing at low concentrations of the drug. Additionally, cytokine release appears lower than other T cell engagers. Overall, it advances the scientific understanding of the potential of NVG-111 in a range of hard-to-treat cancers.”
Poster Presentation Details:
Abstract Number for Publication: 7549
Abstract Title: NVG-111, a novel ROR1xCD3 bispecific antibody for non-Hodgkin lymphoma
Session Title: Poster Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
The abstract is available on the ASCO meeting library.
– Ends –
Tel. +44 (0) 7818 430877
NovalGen is a privately held immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer, with the aim of creating life-saving new treatments for people with cancer. Our dedicated team of experienced scientists, physicians and professionals are passionate about building a pipeline of disruptive and differentiated bispecific antibody products tailored to the needs of the patient.
The company’s lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematologic malignancies and solid tumors using our breakthrough bispecifics technology.
About Chronic Lymphocytic Leukemia (CLL)
CLL is the most common form of leukemia in the Western world and is a type of cancer that begins in the bone marrow. The disease occurs due to a mutation in B lymphocytes, a type of immune cell that fights infection. CLL cells do not fight infection like normal lymphocytes and, over time, the uncontrolled growth of CLL cells in the marrow leads to an increase in the number of CLL cells in the blood.
About Mantle Cell Lymphoma (MCL)
MCL is a cancer of the lymphatic system and is an often-aggressive type of non-Hodgkin lymphoma beginning in the B lymphocytes within the lymph node mantle zone. These B lymphocytes are ineffective in fighting infection and progress to build up in the lymph nodes. If left undiagnosed or uncontrolled over time, the cells can spread to and build up in other parts of the body such as bone marrow and spleen.